(R)-2-(4-chlorophenyl)propanoic acid | 105879-62-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (R)-2-(4-chlorophenyl)propanoic acid
• 英文别名: (2R)-2-(4-chlorophenyl)propanoic acid
• CAS: 105879-62-7
• 化学式: C₉H₉ClO₂
• 分子量: 184.622
• InChiKey: YOZILQVNIWNPFP-ZCFIWIBFSA-N

物化性质

• 沸点：
  297.4±15.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-2-(4-chlorophenyl)propanoic acid 在 叠氮磷酸二苯酯 、 盐酸 作用下， 以 甲苯 为溶剂， 生成 (R)-(+)-1-(4-氯苯基)乙胺
  参考文献：
  名称：

  烯还原酶在水性介质和两相离子液体-水系统中催化（R）-2-芳基丙烯腈的对映选择性合成

  摘要：

  烯还原酶催化的α-亚甲基腈衍生物的对映选择性还原可提供相应的（R）-2-芳基丙腈，并具有较高的转化率。可在水性介质中（与有机助溶剂或通过将底物装载到疏水性树脂上）或在双相离子液体-水系统中研究反应。发现将离子液体与分离的烯还原酶一起使用可改善后处理和底物回收方法。最终手性腈衍生物的合成操作表明如何利用这种生物催化方法制备各种手性化合物。

  DOI：

  10.1002/cctc.201402205
• 作为产物：
  描述：

  (R)-(-)-2-(4'-chlorophenyl)propionamide 在 硫酸 、 溶剂黄146 作用下， 反应 12.0h， 生成 (R)-2-(4-chlorophenyl)propanoic acid
  参考文献：
  名称：

  微生物水解是制备旋光腈，酰胺和羧酸的有效方法

  摘要：

  借助于丁酸红球菌的酶系统，已经将多种芳族腈水解成相应的酰胺和羧酸。该酶促水解可成功地应用于α-芳基丙腈的动力学拆分，从而导致形成（R）-酰胺和（S）-羧酸。

  DOI：

  10.1016/s0040-4039(00)79663-8

文献信息

• Substituted alkyl amido piperidines
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040186103A1

  公开（公告）日：2004-09-23

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种包括该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明提供了一种由结合本发明化合物的治疗有效量和药学上可接受的载体制成的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者施用本发明化合物的有效量以减少受试者的体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。
• Enantioselective Hydrogenation of α-Substituted Acrylic Acids Catalyzed by Iridium Complexes with Chiral Spiro Aminophosphine Ligands
  作者：Shou-Fei Zhu、Yan-Bo Yu、Shen Li、Li-Xin Wang、Qi-Lin Zhou

  DOI：10.1002/anie.201204363

  日期：2012.8.27

  Highly active: Iridium complexes with chiral spiro aminophosphine ligands were synthesized and applied as catalysts for the asymmetric hydrogenation of α‐substituted acrylic acids (see scheme). The complexes were highly active catalysts, showing turnover frequencies of up to 6000 h−1, and catalyst loadings could be reduced to 0.01 mol %.

  高活性：与手性螺环氨基膦配体的铱络合物的合成和作为催化剂用于α-取代的丙烯酸的不对称氢化（参见方案）施用。该复合物具有高活性的催化剂，显示出6000 h最多的周转频率-1，并且催化剂载量可减少到0.01％（摩尔）。
• Enantioselective Synthesis of Chiral Carboxylic Acids from Alkynes and Formic Acid by Nickel‐Catalyzed Cascade Reactions: Facile Synthesis of Profens
  作者：Peng Yang、Yaxin Sun、Kaiyue Fu、Li Zhang、Guang Yang、Jieyu Yue、Yu Ma、Jianrong Steve Zhou、Bo Tang

  DOI：10.1002/anie.202111778

  日期：2022.1.3

  A simple nickel catalyst converts terminal alkynes and formic acid to α-chiral carboxylic acids in high enantioselectivity. The reaction proceeds via the hydrocarboxylation of alkynes and enantioselective transfer hydrogenation of acrylic acids.

  一种简单的镍催化剂以高对映选择性将末端炔烃和甲酸转化为 α-手性羧酸。该反应通过炔烃的加氢羧化和丙烯酸的对映选择性转移氢化进行。
• Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
  申请人：Kelly G. Michael

  公开号：US20070225324A1

  公开（公告）日：2007-09-27

  Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  折环杂环芳基化合物的化学式如下所示： 这些化合物可以制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤等。
• Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof
  申请人：Zhou Qilin

  公开号：US20140194638A1

  公开（公告）日：2014-07-10

  The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 having a value as defined in claim 1 . Starting from the substituted 7-trifluoromesyloxy-7′-diarylphosphino-1,1′-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.

  本发明涉及一种螺环苄胺-膦化合物，其制备方法及用途。该化合物具有如下式（I）所表示的结构，其中n=0至3；R1、R2、R3、R4、R5、R6、R7、R8和R9具有如权利要求1中定义的值。从取代的7-三氟甲烯氧基-7'-二芳基膦基-1,1'-螺二氢茚出发，该化合物经过两步或三步反应合成。新的螺环苄胺-膦化合物与铱前体络合，并经过离子交换，得到包含各种阴离子的铱/螺环苄胺-膦络合物。根据本发明的螺环苄胺-膦/铱络合物可用于催化多种α-取代丙烯酸的不对称加氢，具有高活性和对映选择性，并具有良好的工业化前景。